Peter Kavsak

, PhD, FCACB, FACB

Assistant Professor
Pathology and Molecular Medicine

Division: Clinical Pathology

Discipline of Clinical Chemistry/Immunology
Hamilton Regional Laboratory Medicine Program

Juravinksi Hospital Cancer Centre
Section A, Level 0, Room 118
Hamilton Ontario
Tel: 905-527-4322 x 76293
Fax: 905-381-7066
kavsakp@hhsc.ca

Assistant: Carole Ehler

Currently accepting Graduate Students
Currently accepting Post-Doctoral Fellows

Education and Professional Standing

• PhD Molecular and Medical Genetics, University of Toronto, 2002
• BSc Biochemistry, McGill University, 1997

---

Interests

Research Focus

• Clinical application of new diagnostic tests
• Biomarkers for Diagnostics (cancer & cardiac biomarkers)

Clinical Focus

• Clinical chemistry

Academic Interests

• Undergraduate Medical Foundation Tutor (MF4)
• Post-doctoral clinical chemistry
• Supervise clinical chemistry post-doctoral fellows and medical biochemistry residents

---

Selected Publications

• Kavsak PA, Hirte H, Hotte SJ. Vascular endothelial growth factor concentration as a predictive marker: ready for primetime? Clin Cancer Res. 2010; 16(4):1341.
• Kavsak PA, Jaffe AS. Peripheral blood monocyte subset assessment in non-ST-segment elevation myocardial infarction is required. J Am Coll Cardiol. 2010; 55(2):169-171.
• Kavsak PA, Ko DT, Wang X, Macrae AR, Jaffe AS. 2007 universal myocardial infarction definition change criteria for risk stratification by use of a high-sensitivity cardiac troponin I assay. Clin Chem. 2010; 56(3):487-489.
• Kavsak PA, Worster A, You JJ, Oremus M, Elsharif A, Hill SA, Devereaux PJ, MacRae AR, Jaffe AS. Identification of myocardial injury in the emergency setting. Clin Biochem. 2010; 43(6):539-544.
• Kavsak PA, Newman AM, Ko DT, Macrae AR, Jaffe AS.  The use of a cytokine panel to define the long-term risk stratification of heart failure/death in patients presenting with chest pain to the emergency department. Clin Biochem. 2010; 43(4-5):505-507.
• Kavsak PA. Serial cardiac troponin T measurements in haemodialysis patients: absolute versus changing concentrations? Ann Clin Biochem. 2010; 47(Pt 1):97.
• Kavsak P, Jaffe AS. Sensitive cardiac troponin assays. N Engl J Med. 2009; 361(26):2575-2576.
• Kavsak PA, Wang X, Ko DT, MacRae AR, Jaffe AS. Short-and long-term risk stratification using next-generation, high sensitivity research cardiac troponin I (hs-cTnI) assay in an emergency department chest pain population. Clin Chem. 2009; 55(10):1809-1815.
• Kavsak PA, Henderson M, Ko DT, Wang X, MacRae AR, Jaffe AS. Another potential marker linking gender and cardiac mortality: PAPP-A – a new marker in risk stratification for women presenting with chest pain. Clin Chim Acta. 2009; 408(1-2):139-140.
• Kavsak PA, Henderson M, Moretto P, Hirte H, Evans K, Wong D, Korz W, Hotte SJ. Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agent. Clin Biochem. 2009; 42(10-11):1162-1165.
• Kavsak PA, Wang X, Henderson M, Ko DT, MacRae AR, Jaffe AS. PAPP-A as a marker of increased long-term care risk in patients with chest pain. Clin Biochem. 2009; 42(10-11):1012-1018.
• Kavsak PA, MacRae AR, Yerna MJ, Jaffe AS. Analytic and clinical utility of a next-generation, highly sensitive cardiac troponin I assay for early detection of myocardial injury. Clin Chem. 2009; 55(3):573-577.
• Kavsak PA, Hotte S. Cardiotoxicity associated with sunitinib. Lancet. 2008; 371(9620):1244.